-
Dr. Paul Sargos (Institute Bergonie, Bordeaux, France) presented the first results of the GETUG-AFU 22 study and won the second prize in the EAU20 Best Abstract Awards Oncology.
-
Researchers show that water loss in the cell, the so-called osmotic stress, sets in motion cellular waste disposal, which occurs through an interaction of autophagy and lysosomes; with implications for neurodegenerative diseases.
-
The EUPROMS study represents the first patient-driven quality-of-life (QoL) data collection and revealed specific long-term complaints correlating with a given treatment.
-
Researchers found that medication and psychotherapy do not differ in the acute treatment of individual symptoms. The researchers' goal remains to develop a more individually adapted therapy.
-
Recent studies suggest that steroid sulfatase (STS) can drive prostate cancer and initiate resistance through an alternative androgen synthesis.
-
Some people are better protected against UTIs because their bodies produce higher levels of uromodulin. A research team discovered how the helper protein works, with possible implications for UTI treatment and prevention.
-
A 10-years single-center study reported that substantially more men complain of reduced sexual desire than a decade ago. Conversely, fewer men complain of erectile dysfunction and premature ejaculation.
-
New findings show that urosepsis is associated with lower mortality than sepsis derived from other sites, but if appropriate measures are not taken, 10-15% will develop a recurrent urosepsis.
-
The EAU20 virtual meeting featured a thematic session looking at the controversy in renal cancer surgery considering the timing and necessity of cytoreductive nephrectomy.
-
Prof. Axel Merseburger reviewed the recent evidence testing immuno-oncology (IO) in combination with tyrosine kinase inhibitors (TKIs) in metastatic renal cell carcinoma (mRCC).
-
Pharmacologists have succeeded in detecting minute amounts of the coronavirus SARS-CoV-2 using mass spectrometry in solutions with which COVID-19 patients gargled. The new method could serve as a supplement to previously used tests.
-
Adding docetaxel to antiandrogen treatment improves progression-free survival (PFS) in prostate cancer patients with prostate-specific antigen (PSA) relapse.
-
Aquablation demonstrated a significantly lower rate of sexual dysfunction at the primary safety endpoint of 3 months compared with transurethral resection of the prostate (TURP), according to phase-3 data.
-
In his state-of-the-art lecture, Prof. Leendert Looijenga discussed the connection between infertility and testicular cancer1. Both molecular associations and putative causality were reviewed.
-
New findings from the large, multicentre IRON study demonstrate that robot-assisted partial nephrectomy (RAPN) is associated with lower morbidity and similar oncologic and long-term renal function outcomes compared with open partial nephrectomy (OPN).
-
Labeled prostate-specific membrane antigen in PET-CT fusion was superior in specificity and sensitivity to conventional imaging in pre-treatment staging of intermediate and high-risk localized prostate cancer.
-
The neurological history from male LUTS patients or their partners is essential. Urologists should perform a careful physical exam and perhaps a referral to neurologists prior to any invasive or irreversible treatment.
-
The trial demonstrated a significant survival advantage for intermediate and poor-risk patients with metastatic renal-cell carcinoma who received pembrolizumab + axitinib as compared to those receiving sunitinib.
-
Prof. Yohann Loriot discussed novel treatment options beyond immunotherapy, urging a better understanding of tumor biology towards identifying new targets and facilitating precision medicine.
-
A study investigating nadofaragene firadenovec for high-grade, BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) achieved encouraging, durable, high-grade, recurrence-free survival.
